Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to ...
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 100
- Registration Number
- NCT03812783
- Locations
- 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC
- Conditions
- Interventions
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 150
- Registration Number
- NCT03812770
- Locations
- 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Guangzhou Twelfth People 's Hospita, Guangzhou, Guangdong, China
🇨🇳Kaiping Central Hospital, Kaiping, Guangdong, China
A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 595
- Registration Number
- NCT03794440
- Locations
- 🇨🇳
Hospital of Fudan University, Shanghai, Shanghai, China
HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Sun Yat-sen University
- Registration Number
- NCT03780634
- Locations
- 🇨🇳
Guangzhou Twelfth People 's Hospital, Guangzhou, Guangdong, China
🇨🇳Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Kaiping Central Hospital, Kaiping, Guangdong, China
HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC
- Conditions
- Interventions
- First Posted Date
- 2018-12-13
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 250
- Registration Number
- NCT03775395
- Locations
- 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
- Conditions
- Interventions
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 543
- Registration Number
- NCT03764293
- Locations
- 🇺🇸
Renovatio Clinical, The Woodlands, Texas, United States
🇨🇳The 940th Hospital of the joint logistic support force of People's Liberation Army, Lanzhou, Gansu, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 837
- Registration Number
- NCT03755791
- Locations
- 🇺🇸
Exelixis Clinical Site #88, Philadelphia, Pennsylvania, United States
🇦🇺Exelixis Clinical Site #78, Camperdown, New South Wales, Australia
🇺🇸Exelixis Clinical Site #7, Burlington, Massachusetts, United States
Irradiation Stent Placement Plus TACE for HCC and PVTT
- Conditions
- Interventions
- First Posted Date
- 2018-11-05
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Zhongda Hospital
- Target Recruit Count
- 308
- Registration Number
- NCT03730675
- Locations
- 🇨🇳
Zhong-da Hospital, Southeast University, Nanjing, Jiangsu, China
Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Sun Yat-sen University
- Registration Number
- NCT03722498
- Locations
- 🇨🇳
Guangzhou Twelfth People 's Hospital, Guangzhou, Guangdong, China
🇨🇳Kaiping Central Hospital, Kaiping, Guangdong, China
🇨🇳Ming Shi, Guangzhou, Guangdong, China
DKN-01 Inhibition in Advanced Liver Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Johannes Gutenberg University Mainz
- Target Recruit Count
- 70
- Registration Number
- NCT03645980
- Locations
- 🇩🇪
Universitätsklinikum Schleswig Holstein Campus Lübeck, Lübeck, Germany
🇩🇪Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
🇩🇪Universitätsklinikum Köln, Cologne, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.